Results 191 to 200 of about 37,478 (219)
Some of the next articles are maybe not open access.
Investigation of benign prostatic hyperplasia
Current Opinion in Urology, 2003This is a concise and timely update of the most recent developments in the clinical research on the investigation of benign prostatic hyperplasia.Analysis of the peer-review literature confirms a high level of consensus as to the management of prostatic hyperplasia; analysis of practice trends suggests a satisfactory degree of adoption of the proposed ...
TUBARO, ANDREA +2 more
openaire +3 more sources
Management of Benign Prostatic Hyperplasia
Annual Review of Medicine, 2016Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development.
Eric H, Kim +2 more
openaire +2 more sources
Finasteride for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews, 2009Benign prostatic hyperplasia (BPH), a non-malignant enlargement of the prostate in aging men, can cause bothersome urinary symptoms (intermittency, weak stream, straining, urgency, frequency, incomplete emptying). Finasteride, a five-alpha reductase inhibitor (5ARI), blocks the conversion of testosterone to dihydrotestosterone, reduces prostate size ...
James, Tacklind +4 more
openaire +2 more sources
Cernilton for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews, 1998Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily.
T, Wilt +4 more
openaire +2 more sources
Herbs for Benign Prostatic Hyperplasia
Annals of Pharmacotherapy, 2002OBJECTIVE: To review and evaluate the literature relative to the use of herbal therapies in the treatment of benign prostatic hyperplasia. DATA SOURCES: Literature was identified by MEDLINE, Embase, International Pharmaceutical ...
Lana, Dvorkin, Kathy Y, Song
openaire +2 more sources
Tamsulosin for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews, 2002Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms.This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH ...
T J, Wilt, R, Mac Donald, I, Rutks
openaire +2 more sources
The pathogenesis of benign prostatic hyperplasia
The American Journal of Medicine, 1980Development of prostatic hyperplasia is an almost universal feature of the aging man and dog, and in both species the process develops only in males with intact testes. As the result of studies of plasma hormone levels as a function of age, measurements of the concentration of androgen and of androgen receptor proteins within the prostate, and studies ...
openaire +2 more sources
Tadalafil for benign prostatic hyperplasia
Drug and Therapeutics Bulletin, 2013Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis—Lilly) and for the management of pulmonary arterial hypertension (Adcirca—Lilly).1 The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult
openaire +2 more sources
Pathophysiology of Benign Prostatic Hyperplasia
European Urology, 1994The exact morphogenesis of benign prostatic hyperplasia (BPH) is unknown, but morphologic observations and different etiologic theories, such as the stem cell, dihydrotestosterone, and stromal-epithelial interaction hypotheses, help to explain some of the findings. For example, the initial changes in the development of BPH may result from an activation
openaire +2 more sources
Finasteride and benign prostatic hyperplasia
Drug and Therapeutics Bulletin, 1995Finasteride (Proscar - MSD), a type II 5α-reductase inhibitor, was introduced in 1992 for the medical treatment of men with benign prostatic hyperplasia. The manufacturer claims that finasteride can "halt the progress of the disease and reverse the disease process" and that "one year of therapy with finasteride reversed more than 15 years' growth in ...
openaire +2 more sources